{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T04:17:01Z","timestamp":1789532221016,"version":"build-2803163510"},"reference-count":38,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2011,6,28]],"date-time":"2011-06-28T00:00:00Z","timestamp":1309219200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Nephrology"],"published-print":{"date-parts":[[2011,7]]},"abstract":"<jats:title>ABSTRACT<\/jats:title><jats:p><jats:bold>Aim:\u2003<\/jats:bold> There is little data on the prevalence and severity of dyslipidaemia in Asian patients with lupus nephritis (LN). Whether the dyslipidaemia in LN patients differs from subjects with comparable levels of renal impairment also remains undefined.<\/jats:p><jats:p><jats:bold>Methods:\u2003<\/jats:bold> Lipid profiles of 100 Chinese patients with quiescent LN (age 46.3\u2003\u00b1\u20039.3\u2003years, 83% female, maintenance prednisolone dose 5.80\u2003\u00b1\u20032.43\u2003mg\/day) were studied and compared with 100 controls who had non\u2010lupus non\u2010diabetic chronic kidney diseases (CKD), matched for sex, age and renal function.<\/jats:p><jats:p><jats:bold>Results:\u2003<\/jats:bold> LN patients and CKD controls had similar renal function and proteinuria, while blood pressure was higher in controls. Twenty\u2010five percent of LN patients and 17% of controls were receiving statin treatment. Despite this, 59% of LN patients and 46% CKD controls showed abnormal lipid parameters (<jats:italic>P<\/jats:italic>\u2003=\u20030.066). LN patients showed higher levels of total cholesterol (TC) and triglycerides (TG) than controls (5.28\u2003\u00b1\u20030.12 <jats:italic>vs<\/jats:italic> 4.86\u2003\u00b1\u20030.08\u2003mmol\/L, <jats:italic>P<\/jats:italic>\u2003=\u20030.004; and 1.62\u2003\u00b1\u20030.12 <jats:italic>vs<\/jats:italic> 1.20\u2003\u00b1\u20030.07\u2003mmol\/L, <jats:italic>P<\/jats:italic>\u2003=\u20030.002, respectively). More LN patients had abnormal TC, TG or low\u2010density lipoprotein cholesterol (LDL\u2010C) (54%, 16% and 38%; <jats:italic>P<\/jats:italic>\u2003=\u20030.016, =\u20030.005 and =\u20030.021, respectively). Hydroxychloroquine (HCQ) treatment was associated with lower TC, LDL\u2010C and HDL\u2010cholesterol.<\/jats:p><jats:p><jats:bold>Conclusion:\u2003<\/jats:bold> Dyslipidaemia is prevalent in LN patients and is more severe than controls with a similar degree of CKD despite disease quiescence, low steroid dose and low level of proteinuria. Concomitant corticosteroid and renal impairment are likely contributing factors. HCQ treatment is associated with reduced severity of dyslipidaemia in LN patients.<\/jats:p>","DOI":"10.1111\/j.1440-1797.2011.01456.x","type":"journal-article","created":{"date-parts":[[2011,3,1]],"date-time":"2011-03-01T23:38:20Z","timestamp":1299022700000},"page":"511-517","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":36,"title":["Dyslipidaemia in patients with lupus nephritis"],"prefix":"10.1111","volume":"16","author":[{"given":"YIP BOON","family":"CHONG","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"DESMOND YH","family":"YAP","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"COLIN SO","family":"TANG","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"TAK MAO","family":"CHAN","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2011,6,28]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1191\/0961203306lu2305xx"},{"key":"e_1_2_6_3_2","first-page":"65","volume-title":"Dubois' Lupus Erythematosus","author":"Rus V","year":"2002"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kei142"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.aje.a009122"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.11296"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1002\/1529-0131(200110)44:10<2331::AID-ART395>3.0.CO;2-I"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1191\/096120301669070811"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(87)90762-5"},{"key":"e_1_2_6_10_2","first-page":"1264","article-title":"Lipid profiles in patients with systemic lupus erythematosus","volume":"21","author":"Leong KH","year":"1994","journal-title":"J. Rheumatol."},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1191\/0961203304lu1084xx"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.081097"},{"key":"e_1_2_6_13_2","first-page":"2112","article-title":"Predictors of lipid abnormalities in children with new\u2010onset systemic lupus erythematosus","volume":"34","author":"Tyrrell PN","year":"2007","journal-title":"J. Rheumatol."},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-006-0195-3"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1177\/096120339700600610"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780310706"},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1542-4758.2006.01168.x"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1159\/000186303"},{"key":"e_1_2_6_19_2","first-page":"S2","article-title":"Determinants of patient survival in systemic lupus erythematosus \u2013 focusing on lupus nephritis","volume":"16","author":"Chan TM","year":"2006","journal-title":"Ethn. Dis."},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.1191\/096120300678828541"},{"key":"e_1_2_6_21_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.285.19.2486"},{"key":"e_1_2_6_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2004.04.002"},{"key":"e_1_2_6_23_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780361111"},{"key":"e_1_2_6_24_2","first-page":"777","volume-title":"Clinical Dialysis","author":"Chan TM","year":"2005"},{"key":"e_1_2_6_25_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.21748"},{"key":"e_1_2_6_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(94)90151-1"},{"key":"e_1_2_6_27_2","first-page":"780","article-title":"Longterm beneficial effect of chloroquine diphosphate on lipoprotein profile in lupus patients with and without steroid therapy","volume":"28","author":"Borba EF","year":"2001","journal-title":"J. Rheumatol."},{"key":"e_1_2_6_28_2","first-page":"2142","article-title":"Effect of antimalarial agents on the fasting lipid profile in systemic lupus erythematosus","volume":"27","author":"Tam LS","year":"2000","journal-title":"J. Rheumatol."},{"key":"e_1_2_6_29_2","first-page":"325","article-title":"The cholesterol lowering effect of antimalarial drugs is enhanced in patients with lupus taking corticosteroid drugs","volume":"26","author":"Rahman P","year":"1999","journal-title":"J. Rheumatol."},{"key":"e_1_2_6_30_2","doi-asserted-by":"publisher","DOI":"10.1016\/0167-4889(84)90049-1"},{"key":"e_1_2_6_31_2","doi-asserted-by":"crossref","first-page":"7854","DOI":"10.1016\/S0021-9258(19)40894-6","article-title":"Inhibition of proteolytic degradation of low density lipoprotein in human fibroblasts by chloroquine, concanavalin A, and Triton WR 1339","volume":"250","author":"Goldstein JL","year":"1975","journal-title":"J. Biol. Chem."},{"key":"e_1_2_6_32_2","doi-asserted-by":"crossref","first-page":"8156","DOI":"10.1016\/S0021-9258(17)39707-7","article-title":"Chloroquine inhibits cyclization of squalene oxide to lanosterol in mammalian cells","volume":"259","author":"Chen HW","year":"1984","journal-title":"J. Biol. Chem."},{"key":"e_1_2_6_33_2","doi-asserted-by":"publisher","DOI":"10.1016\/0026-0495(93)90096-7"},{"key":"e_1_2_6_34_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.27300"},{"key":"e_1_2_6_35_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.27289"},{"key":"e_1_2_6_36_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.22156"},{"key":"e_1_2_6_37_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2008.093013"},{"key":"e_1_2_6_38_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.24232"},{"key":"e_1_2_6_39_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahj.2010.08.012"}],"container-title":["Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1440-1797.2011.01456.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1440-1797.2011.01456.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,14]],"date-time":"2023-10-14T08:22:27Z","timestamp":1697271747000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1440-1797.2011.01456.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,6,28]]},"references-count":38,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2011,7]]}},"alternative-id":["10.1111\/j.1440-1797.2011.01456.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1440-1797.2011.01456.x","archive":["Portico"],"relation":{},"ISSN":["1320-5358","1440-1797"],"issn-type":[{"value":"1320-5358","type":"print"},{"value":"1440-1797","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,6,28]]},"assertion":[{"value":"2011-06-28","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}